FOLH1 and prostate carcinoma: Currently, three small-molecule PSMA inhibitors, [68Ga]Ga-PSMA-11, [18F]F-DCFPyL, and flotufolastat F-18, have been approved for PET imaging of prostate cancer by the Food and Drug Administration (FDA).